Promising treatment targeting 40% mortality Candida infection

March 4, 2022
Medical Communications

A Promising Innovation Medicine (PIM) designation has been awarded to rezafungin by the MHRA, for the treatment of invasive candidiasis. …

Anti-inflammatory baricitinib is a life-saving COVID-19 drug

March 4, 2022
Medical Communications

UK experts say they have identified another life-saving drug that can alleviate COVID-19 illness. The anti-inflammatory baricitinib is usually used …

Risk of hospitalisation five times higher with J&J

March 3, 2022
Business Services, Medical Communications

A study published in Jama Network Open has revealed that Johnson & Johnson’s coronavirus vaccine was far less effective at …

FDA grants breakthrough therapy designation to RSV vaccine

March 3, 2022
Business Services, Medical Communications

The FDA has granted a Breakthrough Therapy Designation to Pfizer’s respiratory syncytial virus (RSV) vaccine candidate, for the prevention of …

WHO recommends Merck’s COVID-19 pill

March 3, 2022
Business Services, Medical Communications

WHO have recommended Merck’s pill, molnupiravir, for the treatment of COVID-19 in patients in high risk groups, such as the …

First smart connected insulin pens made available on NHS

March 2, 2022
Research and Development

Today, Novo Nordisk will launch the first smart connected insulin pens to be made available on NHS prescription. The pens, …

Fera Pharmaceuticals receives Orphan Drug Designation from FDA for sickle cell treatment

March 2, 2022
Research and Development

The FDA has granted an Orphan Drug Designation for naproxcinod for the treatment of sickle cell disease, which affects an …

HPV vaccines could mean only one smear test a lifetime

March 2, 2022
Research and Development

A leading scientist has said that women who have the HPV vaccine may need only one smear test to prevent …

FDA share new trial guidelines to further cancer therapy development

March 2, 2022
Research and Development

The FDA has issued three recommendations to industry for clinical trials, to support US President Joe Biden’s relaunch of the …

Moderna faces lawsuit over COVID-19 vaccine

March 1, 2022
Manufacturing and Production

Moderna has been accused of ‘hijacking’ technology from two smaller biotech firms – Arbutus Biopharma and Genevant Sciences – to …

ELUNATE receives commercial approval in Macau

March 1, 2022
Manufacturing and Production

HUTCHMED has received approval to market fruquintinib (ELUNATE in China), a selective and potent oral inhibitor of vascular endothelial growth …

FDA approves CAR-T therapy for multiple myeloma

March 1, 2022
Manufacturing and Production

The FDA gas approved a therapy developed by J&J and its partner Legend Biotech, to treat relapsed or refractory multiple …

First oral diabetes treatment approved in Europe for use during pregnancy

March 1, 2022
Manufacturing and Production

Merck has announced an extension to the label for metformin products in the EU – glucophage (metformin hydrochloride immediate release), …

Potential breakthrough trial for rare disease Hunter syndrome

February 28, 2022
Sales and Marketing

Actigen has initiated a clinical development programme for GNR-055, a potentially breakthrough treatment for the debilitating, life-limiting, rare disease mucopolysaccharidosis …

Phase III data show Dupixent reduced itch in chronic spontaneous urticaria patients

February 28, 2022
Sales and Marketing

Results from a Phase III trial have revealed that adding Dupixent (dupilumab) to standard-of-care antihistamines significanty reduced itch and hives …

Urgent need to address mental health crisis among kidney patients

February 28, 2022
Sales and Marketing

Kidney Research UK has released their findings from a survey of 1,000 kidney disease patients in the UK, revealing the …

Kapruvia receives positive CHMP opinion for pruritus in hemodialysis patients

February 28, 2022
Sales and Marketing

The CHMP has approved Kapruvia (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. …

Study reveals potential genetic determinants of unexplained child deaths

February 25, 2022
Medical Communications

Various genetic determinants may cause a predisposition to Sudden Unexpected Death in Paediatrics (SUPD), which encompasses syndromes such as Sudden …

sydney-rae-jk6kt2jmy4w-unsplash

NICE draft guidance recommends tucatinib for advanced breast cancer

February 25, 2022
Medical Communications

Roughly 400 people with advanced breast cancer are set to benefit from a new treatment, following the NICE publication of …

CHMP recommends QUVIVIQ in Europe as a new treatment for adult insomnia patients

February 25, 2022
Medical Communications

The CHMP has adopted a positive opinion for the use of QUVIVIQ for the treatment of adult patients with insomnia. …

The Gateway to Local Adoption Series

Latest content